Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Clinical trial NCT06364800 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06364800
- Sponsor
- Beijing 302 Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-26
- Primary completion
- 2026-04-26
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.